Gastric cancer stem cells: evidence, potential markers, and clinical implications
Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108, 2015 ). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metasta...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2016-04, Vol.51 (4), p.313-326 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 326 |
|---|---|
| container_issue | 4 |
| container_start_page | 313 |
| container_title | Journal of gastroenterology |
| container_volume | 51 |
| creator | Brungs, Daniel Aghmesheh, Morteza Vine, Kara L. Becker, Therese M. Carolan, Martin G. Ranson, Marie |
| description | Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108,
2015
). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83–e89,
2012
). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145–1157,
2011
). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches. |
| doi_str_mv | 10.1007/s00535-015-1125-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1776092707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714583910</galeid><sourcerecordid>A714583910</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-628257f7133a7d5788ba3d360886f0452137c4fa3935729ad63ad01bcde1a4bf3</originalsourceid><addsrcrecordid>eNp1kV9LHTEQxUOp1FvbD9CXstCXPrh2Jv_XN5FWBUGE9jnkJlmJ3c1ek71Cv71Zrm1tUfKQcOZ3hpkcQj4gHCGA-lIABBMtoGgRqWjFK7JCXhXRUfqarKDjvFYU3ydvS7kFQAZCvyH7VHKqpcQVuT6zZc7RNc4mF3JT5jA2LgxDOW7CffShqofNZppDmqMdmtHmnyGXw8Ym37ghpuiqGsfNUB9znFJ5R_Z6O5Tw_vE-ID--ff1-et5eXp1dnJ5cto5LNreSaipUr5Axq7xQWq8t80yC1rIHLigy5XhvWceEop31klkPuHY-oOXrnh2Qz7u-mzzdbUOZzRjLMrlNYdoWg0pJ6KgCVdFP_6G30zanOt1CCQZaMvxL3dghmJj6ac7WLU3NiUIuNOsQKnX0DFWPD2N0Uwp9rPo_BtwZXJ5KyaE3mxzrN_4yCGaJ0exiNDVGs8RoRPV8fBx4ux6D_-P4nVsF6A4otZRuQn6y0YtdHwBRJKRe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1775308631</pqid></control><display><type>article</type><title>Gastric cancer stem cells: evidence, potential markers, and clinical implications</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Brungs, Daniel ; Aghmesheh, Morteza ; Vine, Kara L. ; Becker, Therese M. ; Carolan, Martin G. ; Ranson, Marie</creator><creatorcontrib>Brungs, Daniel ; Aghmesheh, Morteza ; Vine, Kara L. ; Becker, Therese M. ; Carolan, Martin G. ; Ranson, Marie</creatorcontrib><description>Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108,
2015
). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83–e89,
2012
). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145–1157,
2011
). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-015-1125-5</identifier><identifier>PMID: 26428661</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Biomarkers, Tumor - metabolism ; Cancer ; Care and treatment ; Colorectal Surgery ; Development and progression ; Gastroenterology ; Global Health ; Health aspects ; Hepatology ; Humans ; Medicine ; Medicine & Public Health ; Metastasis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplastic Stem Cells - metabolism ; Prognosis ; Review ; Stem cell research ; Stem cells ; Stomach cancer ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Surgical Oncology</subject><ispartof>Journal of gastroenterology, 2016-04, Vol.51 (4), p.313-326</ispartof><rights>Japanese Society of Gastroenterology 2015</rights><rights>COPYRIGHT 2016 Springer</rights><rights>Japanese Society of Gastroenterology 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-628257f7133a7d5788ba3d360886f0452137c4fa3935729ad63ad01bcde1a4bf3</citedby><cites>FETCH-LOGICAL-c463t-628257f7133a7d5788ba3d360886f0452137c4fa3935729ad63ad01bcde1a4bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-015-1125-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-015-1125-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>313,314,776,780,788,27899,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26428661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brungs, Daniel</creatorcontrib><creatorcontrib>Aghmesheh, Morteza</creatorcontrib><creatorcontrib>Vine, Kara L.</creatorcontrib><creatorcontrib>Becker, Therese M.</creatorcontrib><creatorcontrib>Carolan, Martin G.</creatorcontrib><creatorcontrib>Ranson, Marie</creatorcontrib><title>Gastric cancer stem cells: evidence, potential markers, and clinical implications</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108,
2015
). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83–e89,
2012
). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145–1157,
2011
). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches.</description><subject>Abdominal Surgery</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Colorectal Surgery</subject><subject>Development and progression</subject><subject>Gastroenterology</subject><subject>Global Health</subject><subject>Health aspects</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplastic Stem Cells - metabolism</subject><subject>Prognosis</subject><subject>Review</subject><subject>Stem cell research</subject><subject>Stem cells</subject><subject>Stomach cancer</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Surgical Oncology</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kV9LHTEQxUOp1FvbD9CXstCXPrh2Jv_XN5FWBUGE9jnkJlmJ3c1ek71Cv71Zrm1tUfKQcOZ3hpkcQj4gHCGA-lIABBMtoGgRqWjFK7JCXhXRUfqarKDjvFYU3ydvS7kFQAZCvyH7VHKqpcQVuT6zZc7RNc4mF3JT5jA2LgxDOW7CffShqofNZppDmqMdmtHmnyGXw8Ym37ghpuiqGsfNUB9znFJ5R_Z6O5Tw_vE-ID--ff1-et5eXp1dnJ5cto5LNreSaipUr5Axq7xQWq8t80yC1rIHLigy5XhvWceEop31klkPuHY-oOXrnh2Qz7u-mzzdbUOZzRjLMrlNYdoWg0pJ6KgCVdFP_6G30zanOt1CCQZaMvxL3dghmJj6ac7WLU3NiUIuNOsQKnX0DFWPD2N0Uwp9rPo_BtwZXJ5KyaE3mxzrN_4yCGaJ0exiNDVGs8RoRPV8fBx4ux6D_-P4nVsF6A4otZRuQn6y0YtdHwBRJKRe</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Brungs, Daniel</creator><creator>Aghmesheh, Morteza</creator><creator>Vine, Kara L.</creator><creator>Becker, Therese M.</creator><creator>Carolan, Martin G.</creator><creator>Ranson, Marie</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Gastric cancer stem cells: evidence, potential markers, and clinical implications</title><author>Brungs, Daniel ; Aghmesheh, Morteza ; Vine, Kara L. ; Becker, Therese M. ; Carolan, Martin G. ; Ranson, Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-628257f7133a7d5788ba3d360886f0452137c4fa3935729ad63ad01bcde1a4bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abdominal Surgery</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Colorectal Surgery</topic><topic>Development and progression</topic><topic>Gastroenterology</topic><topic>Global Health</topic><topic>Health aspects</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplastic Stem Cells - metabolism</topic><topic>Prognosis</topic><topic>Review</topic><topic>Stem cell research</topic><topic>Stem cells</topic><topic>Stomach cancer</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brungs, Daniel</creatorcontrib><creatorcontrib>Aghmesheh, Morteza</creatorcontrib><creatorcontrib>Vine, Kara L.</creatorcontrib><creatorcontrib>Becker, Therese M.</creatorcontrib><creatorcontrib>Carolan, Martin G.</creatorcontrib><creatorcontrib>Ranson, Marie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brungs, Daniel</au><au>Aghmesheh, Morteza</au><au>Vine, Kara L.</au><au>Becker, Therese M.</au><au>Carolan, Martin G.</au><au>Ranson, Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric cancer stem cells: evidence, potential markers, and clinical implications</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>51</volume><issue>4</issue><spage>313</spage><epage>326</epage><pages>313-326</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Gastric cancer is a significant global health problem. It is the fifth most common cancer and third leading cause of cancer-related death worldwide (Torre et al. in CA Cancer J Clin 65(2):87–108,
2015
). Despite advances in treatment, overall prognosis remains poor, due to tumour relapse and metastasis. There is an urgent need for novel therapeutic approaches to improve clinical outcomes in gastric cancer. The cancer stem cell (CSC) model has been proposed to explain the high rate of relapse and subsequent resistance of cancer to current systemic treatments (Vermeulen et al. in Lancet Oncol 13(2):e83–e89,
2012
). CSCs have been identified in many solid malignancies, including gastric cancer, and have significant clinical implications, as targeting the CSC population may be essential in preventing the recurrence and spread of a tumour (Dewi et al. in J Gastroenterol 46(10):1145–1157,
2011
). This review seeks to summarise the current evidence for CSC in gastric cancer, with an emphasis on candidate CSC markers, clinical implications, and potential therapeutic approaches.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>26428661</pmid><doi>10.1007/s00535-015-1125-5</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2016-04, Vol.51 (4), p.313-326 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1776092707 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Abdominal Surgery Biomarkers, Tumor - metabolism Cancer Care and treatment Colorectal Surgery Development and progression Gastroenterology Global Health Health aspects Hepatology Humans Medicine Medicine & Public Health Metastasis Neoplasm Metastasis Neoplasm Recurrence, Local Neoplastic Stem Cells - metabolism Prognosis Review Stem cell research Stem cells Stomach cancer Stomach Neoplasms - pathology Stomach Neoplasms - therapy Surgical Oncology |
| title | Gastric cancer stem cells: evidence, potential markers, and clinical implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A07%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20cancer%20stem%20cells:%20evidence,%20potential%20markers,%20and%20clinical%20implications&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Brungs,%20Daniel&rft.date=2016-04-01&rft.volume=51&rft.issue=4&rft.spage=313&rft.epage=326&rft.pages=313-326&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-015-1125-5&rft_dat=%3Cgale_proqu%3EA714583910%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1775308631&rft_id=info:pmid/26428661&rft_galeid=A714583910&rfr_iscdi=true |